Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Len Schleifer
Pharma
Regeneron sees more regulatory issues, sales declines for Eylea
As regulatory delays continue to plague Regeneron's Eylea, quarterly sales for the treatment have dropped below $1B for the first time since 2018.
Kevin Dunleavy
Apr 29, 2026 12:05pm
Regeneron to invest $2B in new Saratoga Springs production plant
Nov 18, 2025 10:15am
JPM25: Regeneron has few answers for declining sales of Eylea HD
Jan 14, 2025 10:25am
Without equity awards, Regeneron's Schleifer made $7M in 2022
Apr 24, 2023 10:32am
Legendary Regeneron chairman Roy Vagelos to retire at age 93
Apr 17, 2023 10:34am
FDA approves Regeneron's Eylea for retinopathy of prematurity
Feb 9, 2023 11:18am
